Bay to Bay News
In Bay to Bay News, Liz S. emphasizes that while the 340B Drug Pricing Program was built on a sound premise, its current implementation has drifted as large, profitable urban hospital systems exploit weak oversight to absorb discounts without passing savings onto patients. Instead, Liz advocates for Congress to focus on domestic reforms, specifically fixing 340B from the inside by requiring strict accountability and proof of patient benefit, rather than pursuing foreign-tied most-favored-nation pricing that threatens to drain pharmaceutical research investment without actually lowering out-of-pocket costs for underserved communities.